Leqembi Approval,Market Prospects for Biogen NASDAQ:BIIB and Eisai

Trading News - The approval of Leqembi, an Alzheimer's drug developed by Biogen in partnership with Eisai, became a significant turning point for both companies. This groundbreaking treatment is the first to receive full FDA approval. However, the news sparked a heated debate within the medical and market communities.

Dr. Alberto Espay, a neurologist from the University of Cincinnati College of Medicine, has raised concerns about the efficacy of Leqembi, noting that the risk for brain swelling and hemorrhage is far higher than any actual improvement. In response, Eisai's U.S. CEO, Ivan Cheung, has defended the drug, asserting its safety and effectiveness for Alzheimer's disease.

The full approval of Leqembi means that Medicare can cover the drug, the federal health insurer for most eligible patients. The Centers for Medicare and Medicaid Services confirmed they are ready to cover 80% of Leqembi's $26,500 cost for patients with early-stage Alzheimer's enrolled in Medicare's Part B drug program.

Despite this, the drug's rollout is expected to be slow due to logistical complexities and capacity limitations at infusion clinics. While sales forecasts project Leqembi to generate annual revenue of $2 billion to $3 billion by 2026, some analysts predict even higher figures if a more convenient injectable drug version is approved.

The recent financial indicators from both companies demonstrate the potential impact of Leqembi's approval. Biogen's stock (ticker: BIIB) decreased 3% during a trading window following the approval. In comparison, Eisai's shares also fell by over 8% at one stage during a Friday trading session but eventually pared some of its losses to close 4.67% lower.

These developments have brought both Eisai and Biogen into the spotlight, and investors and industry analysts alike will closely watch their financial trajectories in the coming years. It is also crucial to consider the potential impact of rival drugs in the market, such as Eli Lilly's (LLY) once-monthly medicine. The success of Leqembi in the market depends not just on the drug's efficacy and safety but also on its ability to outperform potential competitors.
Biogen (NASDAQ: BIIB) has experienced significant fluctuations over the past decade. As seen from its annual and quarterly revenue history from 2010 to 2023, BIIB's revenue has recently declined. BIIB's revenue in Q1 2023 was $2.463 billion, a 2.72% decrease from Q1 2022. The total revenue for the fiscal year ending March 31, 2023, was $10.105 billion, marking a 6.61% decrease YoY. Furthermore, a similar downward trend was observed in the annual revenues for 2022 ($10.173 billion, a 7.36% decline) and 2021. Amidst these financial oscillations, BIIB, in partnership with Eisai Co., Ltd. (ESALF), faced turbulent times in the stock market following the FDA's approval of their Alzheimer's drug, Leqembi.

Leqembi's full approval, being the first Alzheimer's antibody treatment to gain this status, stirred debates within medical and market communities. Notwithstanding its significance in combating Alzheimer's, some medical experts expressed concerns about the drug's efficiency and potential side effects. ESALF's shares dipped by over 8% at one stage during a Friday trading session, although they managed to reduce some losses to close 4.67% lower. BIIB's stock (BIIB), too, witnessed a decrease of 3% during the same trading session.

With the approval of Leqembi, it now falls under Medicare coverage. The Centers for Medicare and Medicaid Services confirmed its readiness to cover 80% of Leqembi's $26,500 cost for patients with early-stage Alzheimer's enrolled in Medicare's Part B drug program. Despite this significant step, Leqembi's rollout may need to be faster due to complexities and capacity limitations at infusion clinics. Nevertheless, some analysts anticipate that Leqembi could generate multibillion-dollar revenues in the coming years.

Conversely, BIIB's gross profit for the March 31, 2023 quarter was $1.800 billion, a slight 1.25% increase YoY. The total gross profit for the year ending March 31, 2023, was $7.917 billion, a 6.13% decline YoY. Conversely, BIIB's operating income for the March 31, 2023 quarter was $0.508 billion, a 16.87% decrease YoY. However, the company reported a substantial surge in its operating income for the year ending March 31, 2023, with a 152.45% increase YoY.

Eisai Co., Ltd. (ESALF) followed a similar path with its financials. As of Q1 2023, ESALF's revenue was JPY 1.034 trillion, a 1.18% increase YoY. However, the total revenue for the fiscal year ending March 31, 2023, was JPY 4.167 trillion, a 5.27% decrease YoY. ESALF's gross profit for the March 31, 2023 quarter was JPY 527.6 billion, a 3.08% increase YoY. Yet, the total gross profit for the fiscal year ending March 31, 2023, declined by 4.18% to JPY 2.109 trillion. ESALF's operating income for the March 31, 2023 quarter was JPY 86.7 billion, a 12.34% decrease YoY. For the fiscal year ending March 31, 2023, ESALF reported an operating income of JPY 365.4 billion, a remarkable 25.9% increase YoY.

The trajectory of ESALF and BIIB will largely depend on the success of Leqembi in the market. Other developments will also influence their financial health in the broader pharmaceutical market. As such, BIIB and ESALF's journey through the financial and medical landscapes is far from over. Their progress will continue to be closely monitored by investors and industry analysts.
That's TradingNEWS